Related Experiment Video
Updated: Jan 7, 2026
04:36
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
803
Acute Myeloid Leukemia With a Non-Canonical FLT3 V491L Mutation: A Case Report With Ex Vivo FLT3 Inhibitors
Mateusz Pospiech1, Michelle P Ngo2, Misk Alrawashdeh2
1Department of Clinical Pharmacy, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA.
Journal of Medical Cases
|January 5, 2026
Summary
This case report details a patient with acute myeloid leukemia (AML) and a rare FLT3 V491L mutation. Gilteritinib showed potential against this mutation, but accessibility issues limited its use.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Approximately 30% of acute myeloid leukemia (AML) patients have FLT3 mutations, linked to poor survival.
- Existing FLT3 inhibitors show limited efficacy against non-canonical mutations.
- This report focuses on a rare FLT3 V491L mutation in an older AML patient with religious restrictions on blood transfusions.
